Investigational drug · Phase 3
OTX-TKI
Also called: axitinib implant
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Neovascular Age-related Macular Degeneration, Neovascular Age-Related Macular Degeneration, Neovascular Age-Related Macular Degeneration (nAMD).
Phase 3Last checked: Nov 20, 2026Latest source record: Jul 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
7
Any phase or sponsor naming "OTX-TKI"
First trial start
2024
Jan 29, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "OTX-TKI", any sponsor or status.
Conditions studied
As listed on its trial records.
- Neovascular Age-related Macular Degeneration
- Neovascular Age-Related Macular Degeneration
- Neovascular Age-Related Macular Degeneration (nAMD)
Approved drugs for the same conditions: Wet macular degeneration · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "OTX-TKI" as an intervention, largest first.
- A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic RetinopathyPivotal-lookingRecruiting
Ocular Therapeutix, Inc.Industry
NCT07235085 · 930 participants (planned) · Start Nov 17, 2025 · Primary completion Mar 2027
Drug: Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24; Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24 · For: Non-Proliferative Diabetic Retinopathy
Sites: Hagerstown, Maryland
Ocular Therapeutix, Inc.Industry
NCT07516132 · 850 participants (planned) · Start Apr 27, 2026 · Primary completion Aug 1, 2030
Drug: OTX-TKI · For: Neovascular Age-Related Macular Degeneration (nAMD)
Sites: Bakersfield, California; Santa Barbara, California; Waterford, Connecticut · 8 sites in all
- Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular DegenerationPivotal-lookingActive, not recruiting
Ocular Therapeutix, Inc.Industry
NCT06495918 · 825 participants (planned) · Start Nov 27, 2024 · Primary completion Jan 8, 2027
Drug: OTX-TKI; Aflibercept and 1 more · For: Neovascular Age-related Macular Degeneration
Sites: Gilbert, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 97 sites in all
- Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular DegenerationPivotal-lookingActive, not recruiting
Ocular Therapeutix, Inc.Industry
NCT06223958 · 344 participants · Start Jan 29, 2024 · Primary completion Apr 29, 2026
Drug: OTX-TKI (axitinib implant); Aflibercept · For: Neovascular Age-Related Macular Degeneration
Sites: Gilbert, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 108 sites in all
Ocular Therapeutix, Inc.Industry
NCT03630315 · 29 participants · Start Feb 18, 2019 · Primary completion Jan 10, 2024
Drug: OTX-TKI; OTX-TKI and 5 more · For: Neovascular Age-related Macular Degeneration
Sites: Sydney, Australia; Adelaide, Australia; Albury, Australia · 6 sites in all
Ocular Therapeutix, Inc.Industry
NCT05695417 · 22 participants · Start Jan 15, 2023 · Primary completion May 28, 2024
Drug: OTX-TKI; Sham · For: Non-proliferative Diabetic Retinopathy
Sites: Phoenix, Arizona; Bakersfield, California; Augusta, Georgia · 10 sites in all
Ocular Therapeutix, Inc.Industry
NCT04989699 · 21 participants · Start Jul 28, 2021 · Primary completion Feb 6, 2023
Drug: OTX-TKI/Sham; Aflibercept/Sham · For: Neovascular Age-Related Macular Degeneration
Sites: Bakersfield, California; Oxnard, California; Altamonte Springs, Florida · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Emerging solutions for neovascular age-related macular degeneration.
Franco JJ, Wubben TJ · Curr Opin Ophthalmol 2026
- Beyond the injection: delivery systems reshaping retinal disease management.
Rowe LW, Akotoye C, Harris A, et al. · Expert Opin Pharmacother 2025
- Exploring new horizons in neovascular age-related macular degeneration: novel mechanisms of action and future therapeutic avenues.
Shirian JD, Shukla P, Singh RP · Eye (Lond) 2025
- The evolving therapeutic landscape of diabetic retinopathy.
Shughoury A, Bhatwadekar A, Jusufbegovic D, et al. · Expert Opin Biol Ther 2023
- Investigational drugs in clinical trials for macular degeneration.
Tolentino MJ, Tolentino AJ · Expert Opin Investig Drugs 2022
- Vascular Endothelial Growth Factor Antagonists: Promising Players in the Treatment of Neovascular Age-Related Macular Degeneration.
Hussain RM, Shaukat BA, Ciulla LM, et al. · Drug Des Devel Ther 2021
Also in development for Neovascular Age-related Macular Degeneration
- IBI302Phase 32 trials
Innovent Biologics (Suzhou) Co. Ltd. · Neovascular Age-related Macular Degeneration, Diabetic Macular Oedema
- Surabgene LomparvovecABBV-RGX-314Phase 32 trials
AbbVie · Diabetic Retinopathy, Neovascular Age-related Macular Degeneration
- ABP 938Phase 31 trial
Amgen · Neovascular Age-related Macular Degeneration, nAMD
- ASKG712AM712, VIS-101Phase 21 trial
Visara, Inc. · Neovascular Age-related Macular Degeneration
- RRG001Phase 21 trial
Shanghai Refreshgene Technology Co., Ltd. · Neovascular Age-related Macular Degeneration
- SAR402663Phase 21 trial
Sanofi · Neovascular Age-related Macular Degeneration
- SYL1801Phase 21 trial
Sylentis, S.A. · Wet Macular Degeneration, Neovascular Age-related Macular Degeneration, Macular Degeneration
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.